Jacques Séguin is a professor of Cardiac Surgery at Paris University. After 20 years of performing over 4,000 open-heart surgeries and authoring more than 200 articles published in peer-reviewed international medical journals, Jacques went on to found several medical technology companies: He was the driving force behind the creation of CoreValve and pioneered the self-expandable TAVR procedure, prior to its acquisition by Medtronic in February 2009 for over $800 million. The CoreValve revalving system was the first TAVR valve to gain CE Mark in May 2007. Jacques also founded ReCor Medical – a company treating high blood pressure by renal denervation acquired by Otsuka (Japan) in 2018. Prof. Séguin continues to create de novo startups but also participates actively in innovative Medtech companies as a board member and investor. He holds, in addition to his MD, a PhD in Biochemistry and Medical History.